Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 647
- Registration Number
- NCT04031703
Patient Report Outcome-Reconstruction and Oncoplastic Cohort
Recruiting
- Conditions
- Breast ReconstructionOncoplastic Breast-conserving SurgeryBreast CancerPatient Reported Outcome Measures
- Interventions
- Procedure: breast reconstructionProcedure: oncoplastic breast-conserving surgery
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2019-07-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10000
- Registration Number
- NCT04030845
- Locations
- 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China
Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Radiation: Conventional fractionated RadiotherapyRadiation: Hypofractionated Radiotherapy
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 4052
- Registration Number
- NCT04025164
- Locations
- 🇨🇳
Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
🇨🇳Suzhou Municipal hospital, Suzhou, Jiangsu, China
🇨🇳The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations
Not Applicable
- Conditions
- Oropharyngeal CarcinomaDe-escalation
- Interventions
- Other: conventional treatmentOther: Toxicities reduced treatment
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 83
- Registration Number
- NCT04012502
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
18F-FES PET/CT's Additional Clinical Value in ER+ BC
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 19
- Registration Number
- NCT04006626
- Locations
- 🇨🇳
Biyun Wang, MD, Shanghai, Shanghai, China
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04001621
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 285
- Registration Number
- NCT04001634
- Locations
- 🇨🇳
Biyun Wang, MD, Shanghai, Shanghai, China
Testing Radical Prostatectomy in Chinese Men With Prostate Cancer and oligoMetastases to the Bone
Not Applicable
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Procedure: Radical prostatectomy plus standard careDrug: Standard of care for metastatic prostate cancer
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT03988686
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Phase 2
Completed
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 75
- Registration Number
- NCT03985046
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma
Phase 2
Completed
- Conditions
- Soft Tissue Sarcoma AdultHigh Grade Sarcoma
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 88
- Registration Number
- NCT03951571
- Locations
- 🇨🇳
Cancer Hospital of Sun Yat-sen, Guangzhou, Guangdong, China
🇨🇳Yunnan Cancer Hospital, Kunming, Yunnan, China
🇨🇳Zhengjiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath